BioCentury
ARTICLE | Clinical News

ALKS 8700: Ph III started

March 17, 2017 1:00 PM UTC

Alkermes began a double-blind Phase III trial to compare 462 mg oral ALKS 8700 twice daily for 5 weeks vs. 240 mg oral Tecfidera dimethyl fumarate twice daily in about 420 patients. The study is part ...

BCIQ Company Profiles

Alkermes plc